ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • microglia
  • Microparticles
  • microparticles and coagulation disorder
  • microparticles and mitochondria
  • microparticles and monocytes
  • microparticles and neutrophils
  • microparticles and pharmacotherapy
  • microparticles and platelets
  • microparticles and rheumatoid arthritis (RA)
  • microparticles and serologic tests
  • Microparticles and systemic lupus erythematosus (SLE)
  • microparticles and systemic sclerosis
  • microparticles and thrombosis
  • MicroRNA
  • MicroRNA and ankylosing spondylitis (AS)
  • MicroRNA and anti-TNF therapy
  • MicroRNA and atherosclerosis
  • MicroRNA and biomarkers
  • MicroRNA and cytokines
  • MicroRNA and dermatomyositis
  • MicroRNA and familial Mediterranean fever
  • MicroRNA and fibroblasts
  • MicroRNA and glucocorticoids
  • MicroRNA and innate immunity
  • MicroRNA and interferons
  • MicroRNA and lupus nephritis
  • MicroRNA and psoriatic arthritis
  • MicroRNA and remission
  • MicroRNA and rheumatoid arthritis
  • MicroRNA and rheumatoid arthritis (RA)
  • MicroRNA and salivary gland
  • MicroRNA and scleroderma
  • MicroRNA and Sjӧgrens
  • MicroRNA and Sjogren's syndrome
  • MicroRNA and SLE
  • MicroRNA and systemic lupus erythematosus (SLE)
  • MicroRNA and systemic sclerosis
  • MicroRNA and vasculitis
  • Microscopic Polyangiitis
  • microsimulation and quality-adjusted life years
  • Microvascular dysfunction
  • microvasculature
  • Midkine
  • Migration inhibitory factor (MIF)
  • milestone
  • milestones
  • military and deployment
  • Milnacipran
  • Mimickers
  • mindfulness
  • mindfulness and Chronic pain
  • mineralization
  • Minority Health
  • mir
  • miR-146a-5p
  • miR15a/16-1
  • miRNA
  • MIS-C
  • Miscellaneous
  • miscellaneous and rheumatic disease
  • Miscellaneous Rheumatic and Inflammatory Diseases
  • Missing data
  • missing data and multiple imputation
  • Mitochondria
  • mitochondria and inflammasome activation
  • mitochondria and monocytes
  • mitochondria and myositis
  • mitochondria and nephritis
  • mitochondria and osteoarthritis
  • mitochondria and rheumatoid arthritis (RA)
  • mitochondria and risk
  • mitochondria and synovium
  • mitochondria and systemic lupus erythematosus (SLE)
  • mitochondria and uric acid
  • Mitochondrial Dysfunction
  • mitogen-activated protein kinase-activated protein kinase-2
  • Mixed Connective Tissue Disease
  • Mixed connective tissue disease (MCTD)
  • Mixed connective tissue disease (MCTD) and outcomes
  • Mixed connective tissue disease (MCTD) and pulmonary fibrosis
  • mixed connective tissue disease (MCTD) and ribonucleoprotein (RNP)
  • Mixed connective tissue disease (MCTD) and rituximab
  • mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE)
  • mixed connective tissue disease (MCTD) and systemic sclerosis
  • MKL1 and BONE EROSION
  • MMF
  • MMP and VDIPEN
  • mobile health apps
  • Model Business
  • modifiable risk
  • modifiable risk and African-Americans
  • modifiable risk and environmental factors
  • modifiable risk and obesity
  • modifiable risk and osteoarthritis
  • modifiable risk and prevention
  • modifiable risk and rheumatoid arthritis (RA)
  • modified stoke ankylosing spondylitis spinal score (MSASSS)
  • modified stoke ankylosing spondylitis spinal score (MSASSS) and bone density
  • modified stoke ankylosing spondylitis spinal score (MSASSS) and psoriatic arthritis
  • modified stoke ankylosing spondylitis spinal score (MSASSS) and radiography
  • modified stoke ankylosing spondylitis spinal score (MSASSS) and risk assessment
  • modified stoke ankylosing spondylitis spinal score (MSASSS) and syndesmophyte
  • modified stoke ankylosing spondylitis spinal score (MSASSS) and x-ray
  • molecular mimicry
  • molecular signature
  • monitoring
  • monoclonal antibodies
  • monoclonal antibodies and cancer treatments
  • monoclonal antibodies and clinical trials
  • monoclonal antibodies and infection
  • monoclonal antibodies and neutrophils
  • monoclonal antibodies and osteoarthritis
  • monoclonal antibodies and pharmacokinetics
  • monoclonal antibodies and psoriatic arthritis
  • monoclonal antibodies and randomized trials
  • monoclonal antibodies and rheumatoid arthritis
  • monoclonal antibodies and rheumatoid arthritis (RA)
  • monoclonal antibodies and rituximab
  • monoclonal antibodies and safety
  • monoclonal antibodies and scleroderma
  • monoclonal antibodies and spondylarthritis
  • monoclonal antibodies and systemic lupus erythematosus (SLE)
  • monoclonal antibodies and technology
  • monoclonal antibodies and vasculitis
  • Monoclonal Gammopathy
  • monocytes
  • monocytes and ANCA
  • monocytes and myositis
  • monocytes and neutrophils
  • monocytes and osteoarthritis
  • monocytes and osteoclastogenesis
  • monocytes and osteoclasts
  • monocytes and pathogenesis
  • monocytes and platelets
  • monocytes and polymyalgia rheumatica
  • monocytes and proteomics
  • monocytes and regulatory cells
  • monocytes and rheumatic disease
  • monocytes and rheumatoid arthritis
  • monocytes and rheumatoid arthritis (RA)
  • monocytes and scleroderma
  • monocytes and signal transduction
  • monocytes and spondylarthritis
  • monocytes and synovial cells
  • monocytes and synovitis
  • monocytes and synovium
  • monocytes and systemic lupus erythematosus (SLE)
  • monocytes and systemic sclerosis
  • monocytes and T cells
  • monocytes and thrombosis
  • monocytes and toll-like receptors
  • monocytes and transcriptional regulation
  • monocytes and transforming growth factor
  • monocytes and tumor necrosis factor (TNF)
  • monocytes and uric acid
  • Monocytes/macrophages
  • monogenic diseases and asthma
  • mononeuritis multiplex
  • Monosodium urate crystals
  • monotherapy and Biologic agents
  • Monozygotic twins
  • month of birth
  • mood
  • morbidity
  • morbidity and mortality
  • morbidity and mortality and ANCA
  • morbidity and mortality and Hispanic patients
  • morbidity and mortality and lung transplant
  • morbidity and mortality and myositis
  • morbidity and mortality and nephritis
  • morbidity and mortality and opportunistic infections
  • morbidity and mortality and osteoarthritis
  • morbidity and mortality and osteoporosis
  • morbidity and mortality and outcomes
  • morbidity and mortality and parathyroid hormone
  • morbidity and mortality and patient-reported outcome measures
  • Morbidity and mortality and polymyalgia rheumatica
  • Morbidity and mortality and polymyositis/dermatomyositis (PM/DM)
  • morbidity and mortality and population studies
  • Morbidity and mortality and psoriatic arthritis
  • morbidity and mortality and race/ethnicity
  • morbidity and mortality and renal disease
  • morbidity and mortality and rheumatic disease
  • morbidity and mortality and rheumatoid arthritis (RA)
  • morbidity and mortality and risk assessment
  • morbidity and mortality and rituximab
  • Morbidity and mortality and sarcoidosis
  • morbidity and mortality and scleroderma
  • morbidity and mortality and sex bias
  • morbidity and mortality and spondylarthritis
  • morbidity and mortality and statins
  • morbidity and mortality and synthetase syndrome
  • Morbidity and mortality and systemic lupus erythematosus (SLE)
  • Morbidity and mortality and systemic sclerosis
  • morbidity and mortality and takayasu arteritis
  • morbidity and mortality and thrombosis
  • morbidity and mortality and tophaceous gout
  • morbidity and mortality and treatment
  • Morbidity and mortality and uric acid
  • morbidity and mortality and vasculitis
  • First |
  • « Previous Page
  • 35
  • 36
  • 37
  • 38
  • 39
  • [40]
  • 41
  • 42
  • 43
  • 44
  • 45
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology